EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan

Sponsor
Bayer
Study ID
NCT01756261
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The objective of this survey is to evaluate effectiveness of EYLEA on Quality of Life (QOL). The QOL is evaluated by using Japanese version (v.1.4 - interviewer administered format) of National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) and compared at baseline and at the 6 and 12 months after start of EYLEA treatment.

Key Dates

Start date
Dec 26, 2012
Status verified
Jun 2018
Primary completion
Jul 20, 2016
Completion
Feb 27, 2017

Study Design

Enrollment
757 participants (actual)

Arms

  • Arm: Group 1

Primary Outcome Measure

Changes in mean NEI-VFQ-25 overall scores of patients after the first intravitreal(ITV) injection of EYLEA [ Time Frame: From baseline to 6 and 12 months ]

Related Studies